Compare USGO & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USGO | CGTX |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | 10 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.1M | 110.8M |
| IPO Year | N/A | 2021 |
| Metric | USGO | CGTX |
|---|---|---|
| Price | $8.26 | $1.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $30.75 | $3.33 |
| AVG Volume (30 Days) | 52.3K | ★ 1.1M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.42 | $0.25 |
| 52 Week High | $17.98 | $3.83 |
| Indicator | USGO | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.17 | 64.39 |
| Support Level | $7.55 | $1.29 |
| Resistance Level | $9.80 | $1.53 |
| Average True Range (ATR) | 0.64 | 0.13 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 28.61 | 81.58 |
US Goldmining Inc is a mineral exploration company with a focus on the exploration and development of a project located in Alaska, USA. The company's primary asset is the 100%-owned Whistler exploration property located in Alaska, USA. It operates and reports in one segment, which focuses on the exploration and development of mineral properties.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).